These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24611982)

  • 1. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.
    van Hagen P; Biermann K; Boers JE; Stoss O; Sleddens HF; van Lanschot JJ; Dinjens WN; Rueschoff J; Wijnhoven BP
    Dis Esophagus; 2015; 28(4):380-5. PubMed ID: 24611982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
    Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
    Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
    Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
    Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
    Jeung J; Patel R; Vila L; Wakefield D; Liu C
    Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
    Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
    Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.
    Koopman T; de Bock GH; Buikema HJ; Smits MM; Louwen M; Hage M; Imholz ALT; van der Vegt B
    Histopathology; 2018 Jan; 72(2):191-200. PubMed ID: 28746978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
    Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
    Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Her-2 in carcinomas of the esophagus.
    Schoppmann SF; Jesch B; Friedrich J; Wrba F; Schultheis A; Pluschnig U; Maresch J; Zacherl J; Hejna M; Birner P
    Am J Surg Pathol; 2010 Dec; 34(12):1868-73. PubMed ID: 21107094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.